Transplantation of haploidentical hematopoietic stem cells from family members without in vitro T-cell depletion for treatment of hematologic malignancies in pediatric patients
- VernacularTitle:亲属单倍体非体外去T细胞造血干细胞移植治疗儿童恶性血液病
- Author:
Daihong LIU
;
Kaiyan LIU
;
Lanping XU
;
Huan CHEN
;
Yuhong CHEN
;
Wei HAN
;
Yu WANG
;
Xiaohui ZHANG
;
Qian JIANG
;
Xiaojun HUANG
- Publication Type:Journal Article
- Keywords:
Hematologic neoplasms;
Hematopoietic stem cell transplantation;
Haploidy;
Child
- From:
Journal of Peking University(Health Sciences)
2004;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of haploidentical(from family member donors) hematopoietic stem cell transplantation(HSCT) for children with hematologic malignancies.Methods: Fifty-eight children under fourteen years with hematological malignancies underwent haploidentical HSCT.All patients had poor-risk clinical or cytogenetic features and reclassified into high-risk and standard-risk groups.Transplantation outcomes were analyzed.Results: Of fifty-eight patient/donor pairs,seven(12.1%) were mismatched in two HLA loci,twenty(34.5%) in three loci,and thirty-one(53.4%) in four loci.Follow-ups were performed for a median of 1 663(752-2 664) days after transplantation.All patients achieved stable engraftments.The cumulative incidence of acute graft-versus-host disease(GVHD) of grades 2-4 was(54.8?7.6)%,and that of grades 3-4 was(11.4?4.8)%.The cumulative incidence of chronic GVHD was(45.6?7.8)% for the total and(19.6?6.5)% for the extensive.Thirty-eight patients survived with a 2-year actual overall rate of survival 59.0% and 78.9% in the high-risk and standard-risk group,respectively.The 3-year probability of LFS was(58.6?8.0)% and(68.4?10.7)%,respectively.Conclusion: The results encourage extending haploidentical HSCT without T-cell depletion treatments to children with an indication for transplantation.
